PortfoliosLab logoPortfoliosLab logo
PBYI vs. TPH
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

PBYI vs. TPH - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Puma Biotechnology, Inc. (PBYI) and Tri Pointe Homes, Inc. (TPH). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, PBYI achieves a 14.45% return, which is significantly lower than TPH's 49.19% return. Over the past 10 years, PBYI has underperformed TPH with an annualized return of -15.39%, while TPH has yielded a comparatively higher 15.92% annualized return.


PBYI

1D
-2.44%
1M
-9.56%
YTD
14.45%
6M
31.21%
1Y
105.43%
3Y*
24.25%
5Y*
-9.60%
10Y*
-15.39%

TPH

1D
-0.04%
1M
0.30%
YTD
49.19%
6M
36.56%
1Y
57.34%
3Y*
16.33%
5Y*
13.64%
10Y*
15.92%
*Multi-year figures are annualized to reflect compound growth (CAGR)

PBYI vs. TPH - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
PBYI
Puma Biotechnology, Inc.
14.45%95.08%-29.56%2.36%39.14%-70.37%17.26%-57.00%-79.41%221.99%
TPH
Tri Pointe Homes, Inc.
49.19%-13.21%2.43%90.42%-33.35%61.68%10.72%42.54%-39.01%56.10%

Correlation

The correlation between PBYI and TPH is 0.13, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.13

Correlation (3Y)
Calculated over the trailing 3-year period

0.22

Correlation (5Y)
Calculated over the trailing 5-year period

0.20

Correlation (10Y)
Calculated over the trailing 10-year period

0.21

Correlation (All Time)
Calculated using the full available price history since Feb 1, 2013

0.21

Fundamentals

Market Cap

PBYI:

$346.26M

TPH:

$4.00B

EPS

PBYI:

$0.48

TPH:

$2.08

PE Ratio

PBYI:

14.25

TPH:

22.59

PS Ratio

PBYI:

1.52

TPH:

1.27

PB Ratio

PBYI:

2.70

TPH:

1.21

Total Revenue (TTM)

PBYI:

$227.21M

TPH:

$3.24B

Gross Profit (TTM)

PBYI:

$169.14M

TPH:

$1.07B

EBITDA (TTM)

PBYI:

$46.97M

TPH:

$274.34M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

PBYI vs. TPH — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PBYI
PBYI Risk / Return Rank: 8383
Overall Rank
PBYI Sharpe Ratio Rank: 8282
Sharpe Ratio Rank
PBYI Sortino Ratio Rank: 7878
Sortino Ratio Rank
PBYI Omega Ratio Rank: 8484
Omega Ratio Rank
PBYI Calmar Ratio Rank: 8888
Calmar Ratio Rank
PBYI Martin Ratio Rank: 8686
Martin Ratio Rank

TPH
TPH Risk / Return Rank: 7979
Overall Rank
TPH Sharpe Ratio Rank: 7474
Sharpe Ratio Rank
TPH Sortino Ratio Rank: 8080
Sortino Ratio Rank
TPH Omega Ratio Rank: 8282
Omega Ratio Rank
TPH Calmar Ratio Rank: 8080
Calmar Ratio Rank
TPH Martin Ratio Rank: 7777
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PBYI vs. TPH - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Puma Biotechnology, Inc. (PBYI) and Tri Pointe Homes, Inc. (TPH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


PBYITPHDifference
Sharpe ratioReturn per unit of total volatility

+0.39

Sortino ratioReturn per unit of downside risk

-0.17

Omega ratioGain probability vs. loss probability

1.35

1.32

+0.02

Calmar ratioReturn relative to maximum drawdown

4.11

2.62

+1.50

Martin ratioReturn relative to average drawdown

9.31

5.80

+3.51

PBYI vs. TPH - Sharpe Ratio Comparison

The current PBYI Sharpe Ratio is 1.52, which is higher than the TPH Sharpe Ratio of 1.13. The chart below compares the historical Sharpe Ratios of PBYI and TPH, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


PBYITPHDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.52

1.13

+0.39

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.13

0.37

-0.50

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.19

0.38

-0.57

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.04

0.18

-0.22

Drawdowns

PBYI vs. TPH - Drawdown Comparison

The maximum PBYI drawdown since its inception was -99.40%, which is greater than TPH's maximum drawdown of -70.06%. Use the drawdown chart below to compare losses from any high point for PBYI and TPH.


Loading charts...

Drawdown Indicators


PBYITPHDifference

Max Drawdown

Largest peak-to-trough decline

-99.40%

-70.06%

-29.34%

Max Drawdown (1Y)

Largest decline over 1 year

-25.78%

-17.47%

-8.31%

Max Drawdown (3Y)

Largest decline over 3 years

-69.59%

-37.97%

-31.62%

Max Drawdown (5Y)

Largest decline over 5 years

-85.86%

-47.00%

-38.86%

Max Drawdown (10Y)

Largest decline over 10 years

-98.76%

-68.38%

-30.38%

Current Drawdown

Current decline from peak

-97.52%

-0.04%

-97.48%

Average Drawdown

Average peak-to-trough decline

-74.42%

-23.88%

-50.54%

Ulcer Index

Depth and duration of drawdowns from previous peaks

11.36%

7.93%

+3.43%

Volatility

PBYI vs. TPH - Volatility Comparison

Puma Biotechnology, Inc. (PBYI) has a higher volatility of 9.68% compared to Tri Pointe Homes, Inc. (TPH) at 0.48%. This indicates that PBYI's price experiences larger fluctuations and is considered to be riskier than TPH based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


PBYITPHDifference

Volatility (1M)

Calculated over the trailing 1-month period

9.68%

0.48%

+9.20%

Volatility (6M)

Calculated over the trailing 6-month period

41.71%

29.53%

+12.18%

Volatility (1Y)

Calculated over the trailing 1-year period

69.92%

40.54%

+29.38%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

75.83%

37.27%

+38.56%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

80.65%

41.98%

+38.67%

Dividends

PBYI vs. TPH - Dividend Comparison

Neither PBYI nor TPH has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

PBYI vs. TPH - Financials Comparison

This section allows you to compare key financial metrics between Puma Biotechnology, Inc. and Tri Pointe Homes, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00500.00M1.00B1.50B20222023202420252026
44.80M
507.90M
(PBYI) Total Revenue
(TPH) Total Revenue
Values in USD except per share items

PBYI vs. TPH - Profitability Comparison

The chart below illustrates the profitability comparison between Puma Biotechnology, Inc. and Tri Pointe Homes, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

20.0%40.0%60.0%80.0%100.0%20222023202420252026
76.8%
98.8%
Portfolio components
PBYI - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Puma Biotechnology, Inc. reported a gross profit of 34.40M and revenue of 44.80M. Therefore, the gross margin over that period was 76.8%.

TPH - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Tri Pointe Homes, Inc. reported a gross profit of 502.02M and revenue of 507.90M. Therefore, the gross margin over that period was 98.8%.

PBYI - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Puma Biotechnology, Inc. reported an operating income of -3.83M and revenue of 44.80M, resulting in an operating margin of -8.5%.

TPH - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Tri Pointe Homes, Inc. reported an operating income of 4.19M and revenue of 507.90M, resulting in an operating margin of 0.8%.

PBYI - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Puma Biotechnology, Inc. reported a net income of -3.80M and revenue of 44.80M, resulting in a net margin of -8.5%.

TPH - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Tri Pointe Homes, Inc. reported a net income of 5.54M and revenue of 507.90M, resulting in a net margin of 1.1%.


Frequently Asked Questions


PBYI and TPH have a correlation of 0.13, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

PBYI has higher volatility (9.68%) compared to TPH (0.48%). In terms of maximum drawdown, PBYI dropped -99.40% vs TPH's -70.06%.

PBYI currently has the higher Sharpe Ratio (1.52 vs 1.13), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for PBYI and TPH

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer